Parsortix platform shown to be compatible with the Roche BenchMark ULTRA automated staining system, with initial study of three key drug targets: HER2 (breast), TROP2 (lung) and PSMA (prostate)
GUILFORD, SURREY AND PLYMOUTH MEETING, PA / ACCESS Newswire / November 5, 2025 / CELLBXHEALTH plc (AIM:CLBX)(OTCQX:ANPCY), a global leader in circulating tumour cell (CTC) intelligence, announces the presentation of a proof-of-concept study using a Roche Tissue Diagnostics workflow at the 16 World ADC conference, San Diego, USA (Nov 3-6). The World ADC Conference is the largest global event dedicated to antibody-drug conjugates (ADCs), attracting over 1,400 attendees focused on advancing targeted cancer therapies.
Roche is a major diagnostics player, holding a significant share of the overall tissue testing market. The Roche BenchMark ULTRA system is considered a world leading clinical automated staining platform, with 95 patient samples processed every minute, equating to more than 50 million samples a year.
The study showcases a novel workflow combining CelLBxHealth's Parsortix platform and proprietary CellKeep slide with Roche's BenchMark ULTRA automated immunohistochemistry (IHC) staining platform for cell visualisation and biomarker analysis across key ADC targets: HER2, TROP2, and PSMA.
Key findings from the collaboration include:
* Blood samples were successfully processed and cancer cell lines fixed and shipped to Roche Tissue Diagnostics' site for automated IHC analysis using Roche Tissue Diagnostics' HER2, TROP2 and PSMA assays
* For all biomarkers the BenchMark ULTRA automated IHC staining was compatible with CelLBxHealth's manual immunofluorescent staining workflow
Characterisation of CTCs can overcome the limitations of tissue biopsies in cancer care. A simple blood test offers a safer, faster, and less costly alternative, enabling repeated testing when tissue isn't available. Since cancer changes over time and with treatment, real-time monitoring is critical. As living cells shed from the tumour into the blood, CTCs provide a dynamic and up-to-date view of the patient's disease status.